Creating bottom-up RNA transfer vehicles from synthetic protein assemblies

Scientists have created a new class of RNA transfer vehicles called synthetic transfer vehicles (STVs), which exhibit superior efficiency in delivering RNA cargo compared to existing methods such as lipid nanoparticles (LNPs) and natural viral vectors. The breakthrough was achieved through the integration of artificial intelligence-driven protein design and bottom-up assembly strategies, resulting in a novel platform capable of targeted RNA delivery across a range of cell types and organisms. The research, published in Nature News, outlines the development of STVs based on synthetic protein assemblies engineered to optimize RNA transport while maintaining structural stability and biocompatibility. The study began with an exploration of how evolutionary pressures shape the architecture of viral capsids, structures that have evolved to efficiently encapsulate and deliver genetic material. Researchers noted that while viral capsids are highly effective in their native environments, their complex, often rigid structures may not always be optimal when repurposed for genetic engineering applications. By leveraging AI-based protein design tools, scientists were able to generate synthetic protein assemblies with tailored geometries and functionalities. These included cyclic, dihedral, and planar symmetries, all of which were previously unexplored in the context of RNA delivery systems. A key innovation in the research was the development of a multidimensional screening system that enabled rapid evaluation of hundreds of synthetic protein configurations. This system identified STV-C8 as the most efficient variant for RNA transfer. STV-C8 is constructed from a planar symmetry and exhibits an open, low-complexity structure that facilitates the loading and release of RNA payloads. Unlike traditional viral vectors, which rely on complex, multi-subunit capsids, STV-C8 demonstrates remarkable simplicity and adaptability. Its design allows for easy modification through the incorporation of computationally designed peptide binders, which enable precise targeting of specific cell types or tissues. To validate the performance of STV-C8, researchers conducted extensive in vitro and in vivo experiments. They tested the vehicle’s ability to deliver a variety of RNA cargoes, including reporter RNAs, gene editors, antiviral agents, and transcription factors, into different cellular models derived from multiple species. The results showed that STV-C8 outperformed both natural viral vectors and LNPs in terms of delivery efficiency and specificity. In addition, a detailed biodistribution analysis in a mouse model revealed that STV-C8 exhibited high tissue penetration and minimal off-target effects, further supporting its potential as a safe and effective delivery tool. One of the most promising applications of STV-C8 emerged in the field of gene therapy. Researchers demonstrated its utility in delivering the CRISPR, Cas9 gene editing system into patient-derived and porcine skeletal muscle cells to target mutations associated with Duchenne muscular dystrophy (DMD). Specifically, they used STV-C8 to remove dystrophin exon 51, a common mutation linked to the disease. This experiment marked a significant step toward developing personalized therapeutic interventions for genetic disorders. Looking ahead, the team plans to expand the scope of STV-C8's applications by exploring its compatibility with other RNA-based therapies and refining its targeting capabilities. The researchers emphasize that the modular nature of STVs allows for continuous optimization, making them adaptable to a wide array of biomedical challenges. As the technology matures, it holds the promise of revolutionizing gene therapy and RNA-based treatments by offering a versatile, efficient, and safer alternative to current delivery platforms.